Ivabradine

What is Ivabradine?

Ivabradine is a selective heart rate-lowering medication that belongs to a unique class of drugs called If channel blockers or funny current inhibitors. It is primarily used to treat chronic heart failure and certain types of chest pain (angina) by reducing heart rate without affecting blood pressure or heart muscle contractility. Unlike traditional heart medications, ivabradine specifically targets the heart’s natural pacemaker to slow the heart rate.

Uses

Ivabradine is approved for several cardiovascular conditions:

• Chronic heart failure: Used in patients with reduced ejection fraction who remain symptomatic despite optimal treatment with ACE inhibitors, beta-blockers, and diuretics
• Chronic stable angina: Prescribed for patients who cannot tolerate beta-blockers or when beta-blockers are contraindicated
• Inappropriate sinus tachycardia: May be used off-label for patients with persistently elevated resting heart rates without identifiable cause
• Postural orthostatic tachycardia syndrome (POTS): Sometimes used off-label to help control excessive heart rate increases upon standing
• Adjunctive therapy: Added to existing heart failure treatment regimens when heart rate remains elevated despite other medications

How it works

Ivabradine works by selectively blocking the If (funny current) channels in the sinoatrial node, which is the heart’s natural pacemaker. These channels are responsible for the spontaneous electrical activity that initiates each heartbeat. By inhibiting these channels, ivabradine slows the heart rate without affecting the force of heart muscle contractions or blood pressure, allowing the heart to work more efficiently and reducing oxygen demand.

Side effects

Common side effects include:

Submit Your Paper

• Visual disturbances (phosphenes or bright flashes of light)
• Blurred vision
• Bradycardia (slow heart rate)
• Headache
• Dizziness
• Fatigue
• Nausea
• High blood pressure

Serious side effects to watch for:

• Atrial fibrillation or other heart rhythm disorders
• Severe bradycardia requiring medical intervention
• Heart block or conduction disorders
• Worsening heart failure symptoms
• Severe visual disturbances affecting daily activities

Warnings and precautions

• Pregnancy and breastfeeding: Should be avoided during pregnancy and breastfeeding due to potential risks to the developing fetus and infant
• Heart rhythm disorders: Contraindicated in patients with sick sinus syndrome, severe heart block, or pacemaker dependence
• Liver impairment: Requires dose adjustment in patients with moderate liver dysfunction and is contraindicated in severe liver disease
• Blood pressure monitoring: Regular monitoring required as ivabradine may increase blood pressure in some patients
• Acute heart failure: Should not be initiated in patients with acute or recently decompensated heart failure

Interactions

Ivabradine has several important drug interactions:

• Strong CYP3A4 inhibitors: Medications like ketoconazole, clarithromycin, and nefazodone significantly increase ivabradine levels and are contraindicated
• Moderate CYP3A4 inhibitors: Drugs such as diltiazem, verapamil, and grapefruit juice require dose reduction of ivabradine
• CYP3A4 inducers: Rifampin, phenytoin, and St. John’s wort may reduce ivabradine effectiveness
• Other heart rate-lowering drugs: Beta-blockers, digoxin, and amiodarone may cause excessive bradycardia when combined
• QT-prolonging medications: Increased risk of heart rhythm abnormalities when used with drugs that prolong QT interval
• Negative inotropes: Non-dihydropyridine calcium channel blockers may enhance heart-slowing effects
• Potassium-depleting diuretics: May increase risk of heart rhythm disorders
• Herbal supplements: Hawthorn and other cardiac herbs may potentiate heart rate-lowering effects

Check interactions with the GMJ Interaction Checker

Dosage

For heart failure, the typical starting dose is 5 mg twice daily, which may be adjusted based on heart rate response. The dose can be increased to 7.5 mg twice daily if the resting heart rate remains above 60 beats per minute, or decreased to 2.5 mg twice daily if the heart rate drops below 50 beats per minute. For chronic stable angina, the usual starting dose is 5 mg twice daily, with possible adjustment to 2.5 mg or 7.5 mg twice daily based on response and tolerance. Patients over 75 years should start with 2.5 mg twice daily. All dosage adjustments should be made under medical supervision, and dosing should be determined by a healthcare provider based on individual patient factors and response.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).